The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing.
Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me.
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that...
David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He...
MRG address issues involving access to care, chronic disease management, patient adherence & compliance to doctors orders, and frees up clinicians time through leveraging...
